CMS issues permanent J-code for Xipere
CMS has issued a permanent product-specific J-code for Xipere, Bausch + Lomb announced in a press release.
Xipere (triamcinolone acetonide injectable suspension) is set to have the code J3299, which will become effective July 1.
Xipere is used to treat patients with macular edema associated with uveitis by utilizing the suprachoroidal space.
“At Bausch + Lomb we are committed to bringing new and innovative therapies to market that benefit eye care professionals and the patients they serve. This not only applies to the development of new therapies, but also making these therapies accessible once they become available,” Yolande Barnard, senior vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, said in the release. “The issuance of the permanent J-code will help facilitate access to Xipere for Americans suffering from macular edema associated with uveitis and help streamline the reimbursement process.”
The FDA approved Xipere in October 2021.